胶质母细胞瘤中的分子标记物和靶向治疗的研究进展  

Recent advances in molecular markers and targeted therapy in glioblastoma

作　　者：王琦雪[1] 赵凯[1] 康春生[1] Wang Qixue;Zhao Kai;Kang Chunsheng(Tianjin Neurological Institute,General Hospital,Tianjin Medical University,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院神经病学研究所,天津300052

出　　处：《中华神经医学杂志》2019年第6期629-633,共5页Chinese Journal of Neuromedicine

摘　　要：多形性胶质母细胞瘤是最常见的中枢神经系统侵袭性恶性肿瘤。胶质母细胞瘤的分子标志物是建立在庞大数据库的基础上,通过大量的研究和算法得到的特异性存在于胶质母细胞瘤中,并且能够反映胶质母细胞瘤发生、发展或者监测其对治疗反应的一类物质。对胶质母细胞瘤分子标志物的筛选和鉴定能够有效区分肿瘤亚型、恶性程度和放化疗的响应性。本文归纳总结胶质母细胞瘤的分子标记物,并且探讨针对它们的靶向治疗的前景。Glioblastoma multiforme (GBM) is one of the most common invasive malignant tumors of the central nervous system. Molecular markers of glioblastoma are screened based on dataset, obtained through a large number of studies and algorithms, and could reflect the occurrence and development of GBM, or monitor the response to treatment. The molecular markers can effectively differentiate the subtypes, malignancy and response to radiotherapy of GBM. Here, we summarize the molecular markers of glioblastoma and discuss the prospects of targeted therapy for GBM.

关 键 词：胶质母细胞瘤 分子标志物 靶向治疗 

分 类 号：R739.4[医药卫生—肿瘤]